KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Co-Diagnostics (CODX) EBIT (2017 - 2025)

Historic EBIT for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to -$7.0 million.

  • Co-Diagnostics' EBIT rose 3147.15% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.5 million, marking a year-over-year increase of 1117.24%. This contributed to the annual value of -$40.1 million for FY2024, which is 614.65% up from last year.
  • Latest data reveals that Co-Diagnostics reported EBIT of -$7.0 million as of Q3 2025, which was up 3147.15% from -$8.1 million recorded in Q2 2025.
  • Co-Diagnostics' EBIT's 5-year high stood at $13.6 million during Q3 2021, with a 5-year trough of -$26.1 million in Q4 2022.
  • Its 5-year average for EBIT is -$4.6 million, with a median of -$8.1 million in 2025.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 105521.15% in 2021, then plummeted by 35338.97% in 2022.
  • Quarter analysis of 5 years shows Co-Diagnostics' EBIT stood at $10.3 million in 2021, then crashed by 353.39% to -$26.1 million in 2022, then surged by 54.73% to -$11.8 million in 2023, then fell by 0.69% to -$11.9 million in 2024, then surged by 41.09% to -$7.0 million in 2025.
  • Its EBIT stands at -$7.0 million for Q3 2025, versus -$8.1 million for Q2 2025 and -$8.6 million for Q1 2025.